Thermo Fisher Scientific Inc. (NYSE:TMO) Position Boosted by Phraction Management LLC

Phraction Management LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 32.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 27,463 shares of the medical research company’s stock after purchasing an additional 6,784 shares during the period. Thermo Fisher Scientific comprises approximately 6.0% of Phraction Management LLC’s portfolio, making the stock its 5th biggest holding. Phraction Management LLC’s holdings in Thermo Fisher Scientific were worth $14,577,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of TMO. International Assets Investment Management LLC raised its holdings in Thermo Fisher Scientific by 61,995.4% during the 4th quarter. International Assets Investment Management LLC now owns 1,009,671 shares of the medical research company’s stock valued at $535,923,000 after acquiring an additional 1,008,045 shares during the period. Loomis Sayles & Co. L P increased its holdings in shares of Thermo Fisher Scientific by 17,046.7% in the third quarter. Loomis Sayles & Co. L P now owns 973,591 shares of the medical research company’s stock worth $492,803,000 after purchasing an additional 967,913 shares during the period. Van ECK Associates Corp increased its holdings in shares of Thermo Fisher Scientific by 2,567.5% in the fourth quarter. Van ECK Associates Corp now owns 352,217 shares of the medical research company’s stock worth $186,954,000 after purchasing an additional 339,013 shares during the period. Rathbones Group PLC increased its holdings in shares of Thermo Fisher Scientific by 111.0% in the third quarter. Rathbones Group PLC now owns 568,970 shares of the medical research company’s stock worth $287,996,000 after purchasing an additional 299,338 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its holdings in shares of Thermo Fisher Scientific by 20.3% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 1,706,179 shares of the medical research company’s stock worth $863,617,000 after purchasing an additional 287,446 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Robert W. Baird reduced their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research note on Thursday, April 25th. The Goldman Sachs Group increased their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target for the company. Finally, Royal Bank of Canada upped their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average target price of $607.35.

Thermo Fisher Scientific Stock Up 0.8 %

Shares of NYSE TMO traded up $4.44 on Wednesday, reaching $573.16. 379,615 shares of the company’s stock traded hands, compared to its average volume of 1,539,744. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The business’s 50 day simple moving average is $574.58 and its two-hundred day simple moving average is $531.67. The company has a market cap of $218.78 billion, a price-to-earnings ratio of 36.48, a price-to-earnings-growth ratio of 2.40 and a beta of 0.80. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 21.59 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were issued a $0.39 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, SVP Michael A. Boxer sold 2,000 shares of the company’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at approximately $7,430,359.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 52,277 shares of company stock worth $29,649,264. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.